Medsafe has received its first application for an oral version of the GLP-1 weight-loss medication Wegovy, 1News reported this week. The move follows a recent decision by Australia’s Therapeutic Goods Administration (TGA) to register the daily tablet, signaling a potential shift in how clinicians may manage obesity in New Zealand.
The transition from weekly injections to daily oral administration represents a significant change in the delivery of semaglutide, the active peptide in Wegovy. While the injectable form has been available in New Zealand since 2025, the daily pill aims to provide an alternative for patients who would prefer not to inject themselves.
Clinical Essentials of Oral Semaglutide
- Mechanism of Action: Semaglutide functions as a glucagon-like peptide-1 (GLP-1) receptor agonist. It mimics the naturally occurring hormone that regulates appetite and digestion, effectively increasing satiety—the feeling of fullness—after eating.
- Administration Protocols: Unlike the weekly injection, the tablet requires daily dosing on an empty stomach with a small amount of water. Patients must wait 30 minutes before consuming food, liquids, or other medications to ensure proper absorption through the stomach lining.
- Regulatory Pathway: Medsafe is considering its first application for an oral GLP-1 drug, though final approval depends on information provided to ensure the product meets international standards for safety, quality and efficacy.
Oral Tablets Deliver Comparable Weight Loss Outcomes
Clinical data suggests that the oral formulation performs comparably to its injectable counterpart. According to reporting from The Conversation, trials have indicated a 14% reduction in body weight for the tablet, compared to approximately 15% for the weekly injection. However, the efficacy of the pill is highly dependent on strict adherence to the daily dosing schedule.
The TGA has registered four distinct strengths for the oral tablets—1.5mg, 4mg, 9mg, and 25mg. Despite the convenience, experts emphasize that these medications are not “magic pills.” As noted by the TGA, the drug is intended for use in conjunction with a reduced-calorie diet and increased physical activity. Medical professionals warn that failing to maintain these lifestyle changes often results in weight regain, with some studies showing participants may recover two-thirds of lost weight within a year of discontinuing therapy.
| Feature | Wegovy Injection | Wegovy Tablet |
|---|---|---|
| Frequency | Once weekly | Once daily |
| Administration | Subcutaneous injection | Oral, empty stomach |
| Wait Period | None | 30 minutes before food/drink |
| Primary Benefit | High convenience | Needle-free option |
Access and Equity in New Zealand Healthcare
While the regulatory application marks a technical milestone, it does not guarantee immediate availability or government funding. Dr. Prabani Wood, Medical Director at the Royal New Zealand College of General Practitioners, noted the importance of ensuring people who need help can access a treatment that works.
The assessment process does not bypass the need for rigorous safety verification. Medsafe has stated it must ensure the product meets international standards for safety, quality, and efficacy, regardless of Australian approval. For patients like Wellington resident Valentina Florez-Betancur, who has been self-funding her GLP-1 journey, the pill represents a potential “maintenance” tool, yet she emphasizes that the medication is merely a component of a much broader effort to manage food cravings and metabolic health.
Consult a General Practitioner Before Starting Treatment
Patients should not combine different formulations of semaglutide. The TGA has explicitly advised against the concomitant use of Wegovy tablets with other GLP-1 receptor agonists.
Individuals considering this treatment should consult their general practitioner to determine if they meet the clinical indications for chronic weight management. A doctor’s assessment is essential to evaluate individual risk factors, particularly for those with a history of cardiovascular disease or other chronic conditions. Professional medical advice is also necessary to monitor for potential muscle loss, which can occur during rapid weight reduction, necessitating a structured approach that includes resistance training and nutritional support.
